Sandoz launches Pyzchiva in US for chronic inflammatory diseases, same indications as Stelara

From Nasdaq: 2025-02-24 01:23:24

Sandoz has launched Pyzchiva in the US, a medicine developed by Samsung Bioepis for treating chronic inflammatory diseases. Pyzchiva has FDA approval and is now available commercially with the same indications as Stelara. Sandoz signed a commercialization agreement with Samsung Bioepis in September 2023, giving them the right to market Pyzchiva in several countries including the US and Canada. For more health news, visit rttnews.com. (RTTNews)



Read more at Nasdaq: Sandoz Reports Commercial Availability Of Pyzchiva In The US – Quick Facts